# Terray Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/terray-therapeutics

- Industry: Biotechnology
- Headquarters: Monrovia, US
- Website: www.terraytherapeutics.com
- Total disclosed funding: $201M
- Latest round: Series B (Oct 17, 2024)
- Investors on record: 12

## About

Terray Therapeutics, Inc. is a Monrovia, US-based biotechnology firm dedicated to innovative drug discovery, utilizing advanced technology platforms to streamline the development of new therapeutics for various diseases, including oncology and autoimmune disorders.Founded in 2018, Terray Therapeutics, Inc. specializes in drug discovery solutions. The company has secured multiple funding rounds, with a notable Series B round raising USD 120.00 mn on October 17, 2024. Eli Berlin is the founder, and Jacob Berlin serves as the CEO. The company operates from its headquarters in Monrovia, California, and has executed a total of 6 deals to date, with a current valuation of USD 344.63 mn.Terray Therapeutics focuses on innovative drug discovery solutions through its proprietary technology platform, which accelerates the development of novel therapeutic compounds. The company offers advanced computational tools and high-throughput screening methods, facilitating the identification of potential drug candidates aimed at oncology and autoimmune disorders. These services cater to pharmaceutical and biotechnology firms seeking to enhance their R&D processes across major markets, including North America, Europe, and Asia-Pacific.Terray Therapeutics generates revenue through partnerships and collaborations with pharmaceutical companies. Its business model includes B2B transactions where clients utilize the company's technology for drug discovery, typically through contracted agreements and joint research initiatives. Clients can access the company's products through subscription-based models or one-time licensing fees, tailored to meet their specific engagement scope and financial capacities.The recent Series B funding round of USD 120.00 mn will be utilized to accelerate drug discovery and development utilizing their AI platform. Plans for future growth include the introduction of new products aimed at enhancing drug development processes, with specific timelines for launches yet to be disclosed. Moreover, Terray Therapeutics is actively seeking to expand its presence in international markets, although specific regions and timelines for this expansion have not been publicly outlined.

## Funding rounds

- Series B, Oct 17, 2024, $120M — Alexandria Venture Investments, Madrona Venture Group, Two Sigma Investments, Goldcrest Capital, Maverick Capital, Digitalis Ventures, Nventures, XTX Ventures, Bedford Ridge Capital
- Series A, Sep 28, 2021, $60M — Alexandria Venture Investments, Madrona Venture Group, Two Sigma Investments, Goldcrest Capital, Digitalis Ventures, KdT Ventures, Sahsen Foundation, XTX Ventures, Greentrail Capital
- Seed, Jun 30, 2021, $16M — Two Sigma Investments, Digitalis Ventures
- Seed, Mar 13, 2019, $5M — Two Sigma Investments, Digitalis Ventures
- Seed, Mar 6, 2019 — KdT Ventures

## Investors

- KdT Ventures (https://capitalatlas.ai/funds/kdt-ventures) — Seed, Series A
- Two Sigma Investments (https://capitalatlas.ai/funds/two-sigma-investments) — Seed, Series A, Series B
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Seed, Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- Madrona Venture Group (https://capitalatlas.ai/funds/madrona-venture-group) — Series A, Series B
- Goldcrest Capital (https://capitalatlas.ai/funds/goldcrest-capital) — Series A, Series B
- Sahsen Foundation — Series A
- XTX Ventures (https://capitalatlas.ai/funds/xtx-ventures) — Series A, Series B
- Greentrail Capital (https://capitalatlas.ai/funds/greentrail-capital) — Series A
- Maverick Capital (https://capitalatlas.ai/funds/maverick-capital) — Series B
- Nventures — Series B
- Bedford Ridge Capital (https://capitalatlas.ai/funds/bedford-ridge-capital) — Series B